SLGL Stock Overview
Together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Sol-Gel Technologies Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.44 |
| 52 Week High | US$1.58 |
| 52 Week Low | US$0.33 |
| Beta | 1.6 |
| 11 Month Change | -34.18% |
| 3 Month Change | -36.54% |
| 1 Year Change | -68.36% |
| 33 Year Change | -94.74% |
| 5 Year Change | -94.53% |
| Change since IPO | -96.77% |
Recent News & Updates
Recent updates
Will Sol-Gel Technologies (NASDAQ:SLGL) Spend Its Cash Wisely?
Feb 28
Here's Why We're Watching Sol-Gel Technologies' (NASDAQ:SLGL) Cash Burn Situation
Nov 07Companies Like Sol-Gel Technologies (NASDAQ:SLGL) Are In A Position To Invest In Growth
Jul 21Sol-Gel Technologies GAAP EPS of $0.01 beats by $0.11, revenue of $3.5M misses by $1.11M
Aug 04These Analysts Think Sol-Gel Technologies Ltd.'s (NASDAQ:SLGL) Sales Are Under Threat
May 17We Think That There Are Issues Underlying Sol-Gel Technologies' (NASDAQ:SLGL) Earnings
Apr 15Downgrade: Here's How Analysts See Sol-Gel Technologies Ltd. (NASDAQ:SLGL) Performing In The Near Term
Apr 05We Think Sol-Gel Technologies (NASDAQ:SLGL) Can Afford To Drive Business Growth
Nov 23We Think Sol-Gel Technologies (NASDAQ:SLGL) Needs To Drive Business Growth Carefully
Aug 04Here's Why Sol-Gel Technologies Ltd.'s (NASDAQ:SLGL) CEO May Deserve A Raise
Jul 01Sol-Gel says no FDA notification regarding its marketing application for EPSOLAY
Apr 27Newsflash: Sol-Gel Technologies Ltd. (NASDAQ:SLGL) Analysts Have Been Trimming Their Revenue Forecasts
Mar 05We're Not Very Worried About Sol-Gel Technologies' (NASDAQ:SLGL) Cash Burn Rate
Feb 02What Type Of Returns Would Sol-Gel Technologies'(NASDAQ:SLGL) Shareholders Have Earned If They Purchased Their SharesYear Ago?
Dec 29
FDA accepts Sol-Gel application for Twyneo
Dec 07Sol-Gel: Slow And Steady Topical Technology
Nov 19These Analysts Think Sol-Gel Technologies Ltd.'s (NASDAQ:SLGL) Sales Are Under Threat
Nov 18Sol-Gel Technologies EPS beats by $0.09, beats on revenue
Nov 12Shareholder Returns
| SLGL | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -16.8% | -3.8% | -1.0% |
| 1Y | -68.4% | 9.8% | 30.3% |
Return vs Industry: SLGL underperformed the US Pharmaceuticals industry which returned 8.7% over the past year.
Return vs Market: SLGL underperformed the US Market which returned 30.4% over the past year.
Price Volatility
| SLGL volatility | |
|---|---|
| SLGL Average Weekly Movement | 15.3% |
| Pharmaceuticals Industry Average Movement | 9.6% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: SLGL's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: SLGL's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 36 | Alon Seri-Levy | www.sol-gel.com |
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. In addition, the company is also involved in the development of generic topical dermatological drug products.
Sol-Gel Technologies Ltd. Fundamentals Summary
| SLGL fundamental statistics | |
|---|---|
| Market cap | US$12.01m |
| Earnings (TTM) | -US$9.57m |
| Revenue (TTM) | US$11.71m |
1.0x
P/S Ratio-1.3x
P/E RatioIs SLGL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SLGL income statement (TTM) | |
|---|---|
| Revenue | US$11.71m |
| Cost of Revenue | US$16.78m |
| Gross Profit | -US$5.07m |
| Other Expenses | US$4.50m |
| Earnings | -US$9.57m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.34 |
| Gross Margin | -43.31% |
| Net Profit Margin | -81.75% |
| Debt/Equity Ratio | 0% |
How did SLGL perform over the long term?
See historical performance and comparison